Selective ATP-Competitive Inhibitors of TOR Suppress Rapamycin-Insensitive Function of TORC2 in S. cerevisiae

Abstract The target of rapamycin (TOR) is a critical regulator of growth, survival and energy metabolism. The allosteric TORC1 inhibitor rapamycin has been used extensively to elucidate the TOR related signal pathway but is limited by its inability to inhibit TORC2. We used an unbiased cell proliferation assay of a kinase inhibitor library to discover QL-IX-55 as a potent inhibitor of S. cerevisiae growth. The functional target of QL-IX-55 is the ATP-binding site of TOR2 as evidenced by the discovery of resistant alleles of TOR2 through rational design and unbiased selection strategies. QL-IX-55 is capable of potently inhibiting both TOR complex 1 and 2 (TORC1 and TORC2) as demonstrated by biochemical IP kinase assays (IC50: <50 nM) and cellular assays for inhibition of substrate YPK1 phosphorylation. In contrast to Rapamycin, QL-IX-55 is capable of inhibiting TORC2-dependent transcription which suggests that this compound will be a powerful probe to dissect the Tor2/TORC2 related signaling pathway in yeast. The resurgence of pathogenic yeast infections has stimulated interest in developing new classes of antifungal agents.(

[1]  Terry D. Foutz,et al.  Identification of a small molecule yeast TORC1 inhibitor with a multiplex screen based on flow cytometry. , 2012, ACS chemical biology.

[2]  Peter Dinér,et al.  Design, Synthesis, and Characterization of a Highly Effective Hog1 Inhibitor: A Powerful Tool for Analyzing MAP Kinase Signaling in Yeast , 2011, PloS one.

[3]  D. Sabatini,et al.  Mammalian Target of Rapamycin ( mTOR ) Inhibitor for Treatment of Cancer , 2011 .

[4]  D. Sabatini,et al.  Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. , 2010, Journal of medicinal chemistry.

[5]  Lisa L. Smith,et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.

[6]  Kevin Curran,et al.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. , 2009, Cancer research.

[7]  M. Arendrup,et al.  Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[9]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[10]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[11]  J. Yates,et al.  Probing the membrane environment of the TOR kinases reveals functional interactions between TORC1, actin, and membrane trafficking in Saccharomyces cerevisiae. , 2007, Molecular biology of the cell.

[12]  M. Hall,et al.  Mutual Antagonism of Target of Rapamycin and Calcineurin Signaling* , 2006, Journal of Biological Chemistry.

[13]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[14]  M. Gerstein,et al.  Global analysis of protein phosphorylation in yeast , 2005, Nature.

[15]  R. Loewith,et al.  Tor2 Directly Phosphorylates the AGC Kinase Ypk2 To Regulate Actin Polarization , 2005, Molecular and Cellular Biology.

[16]  Marco Foiani,et al.  DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1 , 2004, Nature.

[17]  John E. Scott,et al.  Discovery of Cercosporamide, a Known Antifungal Natural Product, as a Selective Pkc1 Kinase Inhibitor through High-Throughput Screening , 2004, Eukaryotic Cell.

[18]  Carlos L Arteaga,et al.  Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? , 2004, Cancer cell.

[19]  J. Crespo,et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.

[20]  A. Goffeau,et al.  The Effects of Transcription Regulating Genes PDR1, pdr1-3 and PDR3 in Pleiotropic Drug Resistance , 2001, Proteomics.

[21]  Ted Powers,et al.  Mechanism of Metabolic Control , 2000, The Journal of cell biology.

[22]  J. Thornton,et al.  Mitochondria-to-nuclear signaling is regulated by the subcellular localization of the transcription factors Rtg1p and Rtg3p. , 2000, Molecular biology of the cell.

[23]  J. Kunz,et al.  TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. , 1994, Molecular biology of the cell.

[24]  J. Kunz,et al.  Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression , 1993, Cell.

[25]  J. Heitman,et al.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.

[26]  M. Vidal,et al.  The yeast gene ERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle-sparking sterol , 1989, Molecular and cellular biology.

[27]  D. Botstein,et al.  Plasmid construction by homologous recombination in yeast. , 1987, Gene.